Objective: To analyse the economic impact of galantamine, based on basic activities of daily living (ADL).; Methods: Data were derived from Swedish patients enrolled in a 6-month placebo-controlled trial of galantamine (GAL-INT-1; n=80), and from the Kungsholmen-Nordanstig Project, a longitudinal study of 919 elderly persons in Sweden. Basic ADL were assessed using the Katz’ Index […]
Background: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer’s disease (AD). Here we report its efficacy in patients with severe AD.; Methods: Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing […]
To address socioeconomic challenges associated with its increasing prevalence, data are needed on country-level resource use and costs associated with Alzheimer’s disease (AD). GERAS is an 18-month observational study being conducted in France, Germany, and the UK (with an 18-month extension in France and Germany), aimed at determining resource use and total costs associated with […]
Objective: To investigate the use of formal care during the first three years after diagnosis of mild dementia and identify cost-predicting factors. Design: Prospective longitudinal study over three years. Setting: An incidence-based bottom–up cost-of-illness study where information about formal health care services was drawn from the municipalities’ registers during the first three years after the […]